MRK · News · 20260911N

Keytruda Patent Expiration Outlook

Merck & Co., Inc. · 2026-09-11 · Importance 64 · Surprise 42 · In source text

Merck is expanding its pipeline and newer drug portfolio to offset Keytruda’s loss of exclusivity expected in 2028. The company’s long-term growth strategy therefore depends on advancing replacement medicines and diversifying revenue beyond Keytruda. Third-party reporting identifies the 2028 patent cliff as a material strategic and outlook risk, although no specific pipeline revenue or investment amount was disclosed.

Key facts

• The news digest notes an upcoming Keytruda patent cliff / loss of exclusivity in 2028. source
• The Manufacturers Life Insurance Company increased its stake in Merck by 12.3% in the second quarter, bringing its total holdings to over 2 million shares valued at $266.4 million. source
• Smith Chas P & Associates PA Cpas has a $46.21 million stake in Merck after reducing its holdings by 2.2% in the second quarter. source
• IPG Investment Advisors LLC reduced its stake in Merck by 82.9% in the second quarter, selling 13,125 shares and retaining 2,702 shares. source
• Company insiders have sold nearly $30 million worth of Merck shares in the last 90 days. source
• Merck reported strong quarterly revenues exceeding expectations and declared a quarterly dividend. source
• Representative Maria Elvira Salazar purchased between $15,001 and $50,000 worth of Merck & Co., Inc. (NYSE:MRK) stock on August 19th through her UBS IRA account. source
• Analysts maintain a "Moderate Buy" rating for Merck with an average price target of $151.32. source

Impact estimates